Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:

To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.

This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gary E. Stein, Pharm.D.
• Collaborator: Astellas Pharma US, Inc.
• Treatments: Caspofungin; Echinocandins; Micafungin

Criteria

Inclusion Criteria:

• Adult patients with presumptive candidemia

Exclusion Criteria:

• Patients with severe neutropenia (<500)

• Patients with APACHE II scores > 20

• Patients with severe liver disease